Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials

By sjmartinez • October 30, 2023

Cheema HA, Shafiee A, Athar MMT, Rafiei MA, Mehmannavaz A, Jafarabady K, Shahid A, Ahmad A, Ijaz SH, Dani SS, Minhas AMK, Nashwan AJ, Fudim M, Fonarow GC. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials. Front Cardiovasc Med. 2023 Oct 12;10:1273781. doi: 10.3389/fcvm.2023.1273781. PMID: 37900570; PMCID: PMC10602781.

Tags: Cardiology/Epi, dapagliflozin, empagliflozin, heart failure, HFPEF, Publications, SGLT2I

A randomized controlled trial of pulsed field ablation vs antiarrhythmic therapy as a first-line treatment for persistent atrial fibrillation: The AVANT GUARD trial rationale and design

Wazni OM, Chun KJ, Amin A, Anic A, Ajijola OA, Gibson DN, Mansour M, Makati K, Chrispin J, Duytschaever M, Nair DG, Piccini JP, Natale[...]

Cardiac Myxoma With Atypical Presentation Leading to Delayed Diagnosis: A Case Report

Alishala M, Trinh T, Lee JS. Cardiac Myxoma With Atypical Presentation Leading to Delayed Diagnosis: A Case Report. Cureus. 2026 Feb 26;18(2):e104308. doi: 10.7759/cureus.104308. PMID:[...]

Effect of APOC3 Inhibition with Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study

Marston NA, Bergmark BA, Prohaska TA, Moura FA, Zimerman A, Alexander VJ, Kang YM, Weinland J, Ran X, Murphy SA, Zhang S, Li D, Banach[...]